Besides the EPR effect-based tumor targeting and CD44-driven tumor targeting as described above [52], HA could also work in a tumor microenvironment to trigger the reprogramming of tumor-associated macrophages towards anti-tumor M1 type macrophages. The gene discussed is CD44; the disease is neoplasm.